Patterson et al. showed COVID spike protein (virus infection & thus vaccine) persisting in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months (at least 15 months)

by Paul Alexander

This implies the need to detoxify and dissolve spike protein to prevent it from doing damage especially to the vasculature; post-acute sequelae (PASC) of COVID may affect up to 30-40% of all infected

‘investigated the presence of SARS-CoV-2 S1 (sub-unit) protein in 46 individuals.

analyzed T-cell, B-cell, and monocytic subsets in both severe COVID-19 patients and in patients with post-acute sequelae of COVID-19 (PASC).

The levels of both intermediate (CD14+, CD16+) and non-classical monocyte (CD14Lo, CD16+) were significantly elevated in PASC patients up to 15 months post-acute infection compared to healthy controls (P=0.002 and P=0.01, respectively).

A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection. Non-classical monocytes were sorted from PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein was confirmed by mass spectrometry. Cells from 4 out of 11 severe COVID-19 patients and 1 out of 26 PASC patients contained ddPCR+ peripheral blood mononuclear cells, however, only fragmented SARS-CoV-2 RNA was found in PASC patients. No full length sequences were identified, and no sequences that could account for the observed S1 protein were identified in any patient. That non-classical monocytes may be a source of inflammation in PASC warrants further study.’